Finance

Lists
Why is MCRB down 4,48%?
Dive Deeper
MCRB:NASDAQ
Seres Therapeutics Inc
2,56 US$
-4,48%
(-0,12) 1D
13 ოქტ, 12:34:42 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MCRB...
Open
2,66 US$
High
2,66 US$
Low
2,51 US$
Mkt. cap
25,45 მლნ.
Avg. vol.
71,56 ათ.
Volume
16,89 ათ.
52-wk high
29,98 US$
52-wk low
2,42 US$
EPS
-2,33 US$
Beta
0,31
Shares outstanding
9,94 მლნ.
No. of employees
66
Open
2,66 US$
High
2,66 US$
Low
2,51 US$
Mkt. cap
25,45 მლნ.
Avg. vol.
71,56 ათ.
Volume
16,89 ათ.
52-wk high
29,98 US$
52-wk low
2,42 US$
EPS
-2,33 US$
Beta
0,31
Shares outstanding
9,94 მლნ.
No. of employees
66
News stories
From web sources and news partners
About Seres Therapeutics Inc
CEOერიკ შაფ
Employees66
Founded2010
Headquarters-
Sector-
Analyst ratings
Based on 2 analysts giving stock ratings to MCRB in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for MCRB in the last 3 months.
Highest
Current 2,56 US$
22,00 US$ (+759,38%)
Average
17,00 US$ (+564,06%)
Lowest
12,00 US$ (+368,75%)
Analyst
Recommendation
Action
Price target
Projected
Date
John Newman
Canaccord Genuity
Buy
Maintained
22,00 US$
+759,4%
08/06/2026
Matthew Keller
H.C. Wainwright
Buy
Reiterated
12,00 US$
+368,7%
08/05/2026
Edward Tenthoff
Piper Sandler
Hold
Maintained
20,00 US$
+681,2%
02/13/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
11/05/2025
Last report
5 აგვ. 2026
Fiscal period
Q2 2026
1,07 US$ / -2,18 US$
+148,77%beat
Revenue / Est. (USD)
736,00 ათ. / 358,00 ათ.
+105,59%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
351,00 ათ.
438,00 ათ.
358,00 ათ.
736,00 ათ.
Cost of goods sold
13,35 მლნ.
12,28 მლნ.
13,20 მლნ.
9,14 მლნ.
Cost of revenue
13,35 მლნ.
12,28 მლნ.
13,20 მლნ.
9,14 მლნ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9,48 მლნ.
7,54 მლნ.
8,07 მლნ.
7,06 მლნ.
Operating expense
9,48 მლნ.
7,54 მლნ.
8,07 მლნ.
7,06 მლნ.
Total operating expenses
22,83 მლნ.
19,82 მლნ.
21,26 მლნ.
16,20 მლნ.
Operating income
-22,48 მლნ.
-19,38 მლნ.
-20,91 მლნ.
-15,47 მლნ.
Other non operating income
2,84 მლნ.
2,33 მლნ.
669,00 ათ.
673,00 ათ.
EBT including unusual items
8,20 მლნ.
-15,34 მლნ.
-19,91 მლნ.
4,58 მლნ.
EBT excluding unusual items
-19,02 მლნ.
-16,60 მლნ.
-19,91 მლნ.
-14,61 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
8,20 მლნ.
-15,34 მლნ.
-19,91 მლნ.
4,58 მლნ.
Net profit margin
2 337,32%
-3 501,14%
-5 562,29%
622,42%
Earnings per share
0,94
-1,76
-2,08
1,07
Interest and investment income
618,00 ათ.
445,00 ათ.
325,00 ათ.
181,00 ათ.
Interest expense
-
-
-
-
Net interest expenses
618,00 ათ.
445,00 ათ.
325,00 ათ.
181,00 ათ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-21,43 მლნ.
-18,42 მლნ.
-20,13 მლნ.
-14,80 მლნ.
Gain or loss from assets sale
-
-192,00 ათ.
-
139,00 ათ.
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები